T-Cell CD27 Expression Assessed for Smear-Negative Tuberculosis
By LabMedica International staff writers Posted on 27 Jul 2021 |

Image: The Cytomics FC500 Flow Cytometer System (Photo courtesy of Beckman Coulter Life Sciences)
Mycobacterium tuberculosis (MTB) and its related disease tuberculosis (TB) are infectious diseases with a worldwide focus. Although both vaccines and anti-TB drugs are available, there is a global focus on illness diagnosis in smear-negative and latent tuberculosis infectious populations (SN-TB and LTBI).
To a great extent, the cell-mediated immune response is involved in and regulates MTB, and CD4 T cells are thought to play a significant role in controlling MTB infection. CD27, a member of the TNF-receptor superfamily, is inextricably expressed on the mature pathogen-specific CD4+ T cell surface.
Pathogen Biologists at Nantong University (Nantong, China) and their colleagues include in a study 56 SN-TB patients, all had negative detection of sputum at least three times and sputum negative-culture results; an human control (HC) group that included 34 participants with no exposure to MTB and no clinical characteristics of TB, and the Tuberculosis Skin Test (PPD) test was negative; and 46 doctors and nurses working closely with TB patients for at least 1 year (TB-C group.)
All 56 smear-negative TB patients included in the study had peripheral blood collected and sputum collected at least three times for Ziehl-Neelsen acid-fast stain. Sputum culture was carried out by BACTEC MGIT 960 (Becton Dickinson, Sparks, MD, USA), liquid culture isolates using the GenoTypeH test system (Hain Lifescience, Nehren, Germany) and improved L-J culture medium. T-SPOT (tuberculosis infectious T-lymphocyte spot assay, Oxford Immunotec, Abingdon, UK) results were obtained from the clinical laboratory. For detection of the whole blood cell surface markers “CD27−CD4+” T cells, cells were collected, washed and analyzed by a Beckman Coulter FC500 flow cytometry analysis system (Indianapolis, IN, USA).
The scientists observed that the percentages of “CD27−IFN-γ+CD4+” cells were significantly increased in the SN-TB group compared with the HC and TB-C groups (AUC was 0.88, sensitivity was 82.14%, and specificity was 80.0%). The percentage of “CD27−IFN-γ+CD4+” cells was negatively correlated with white blood cell count (WBC) and positively correlated with immunoglobulin E (IgE). Furthermore, “CD27−IFN-γ+CD4+” cells were significantly decreased, especially in the > 50 years group, after clinical treatment.
The authors concluded that they had demonstrated the increased expression of “CD27−IFN-γ+CD4+” cells in smear-negative TB patients and evaluated its changes after normal anti-TB therapy. These data suggested that “CD27−IFN-γ+CD4+” T cells could be used to assist the diagnosis of TB and more accurately evaluate the treatment outcome of smear-negative TB. The study was published on June 27, 2021 in the journal BMC Immunology.
Related Links:
Nantong University
Becton Dickinson
Hain Lifescience
Oxford Immunotec
Beckman Coulter
To a great extent, the cell-mediated immune response is involved in and regulates MTB, and CD4 T cells are thought to play a significant role in controlling MTB infection. CD27, a member of the TNF-receptor superfamily, is inextricably expressed on the mature pathogen-specific CD4+ T cell surface.
Pathogen Biologists at Nantong University (Nantong, China) and their colleagues include in a study 56 SN-TB patients, all had negative detection of sputum at least three times and sputum negative-culture results; an human control (HC) group that included 34 participants with no exposure to MTB and no clinical characteristics of TB, and the Tuberculosis Skin Test (PPD) test was negative; and 46 doctors and nurses working closely with TB patients for at least 1 year (TB-C group.)
All 56 smear-negative TB patients included in the study had peripheral blood collected and sputum collected at least three times for Ziehl-Neelsen acid-fast stain. Sputum culture was carried out by BACTEC MGIT 960 (Becton Dickinson, Sparks, MD, USA), liquid culture isolates using the GenoTypeH test system (Hain Lifescience, Nehren, Germany) and improved L-J culture medium. T-SPOT (tuberculosis infectious T-lymphocyte spot assay, Oxford Immunotec, Abingdon, UK) results were obtained from the clinical laboratory. For detection of the whole blood cell surface markers “CD27−CD4+” T cells, cells were collected, washed and analyzed by a Beckman Coulter FC500 flow cytometry analysis system (Indianapolis, IN, USA).
The scientists observed that the percentages of “CD27−IFN-γ+CD4+” cells were significantly increased in the SN-TB group compared with the HC and TB-C groups (AUC was 0.88, sensitivity was 82.14%, and specificity was 80.0%). The percentage of “CD27−IFN-γ+CD4+” cells was negatively correlated with white blood cell count (WBC) and positively correlated with immunoglobulin E (IgE). Furthermore, “CD27−IFN-γ+CD4+” cells were significantly decreased, especially in the > 50 years group, after clinical treatment.
The authors concluded that they had demonstrated the increased expression of “CD27−IFN-γ+CD4+” cells in smear-negative TB patients and evaluated its changes after normal anti-TB therapy. These data suggested that “CD27−IFN-γ+CD4+” T cells could be used to assist the diagnosis of TB and more accurately evaluate the treatment outcome of smear-negative TB. The study was published on June 27, 2021 in the journal BMC Immunology.
Related Links:
Nantong University
Becton Dickinson
Hain Lifescience
Oxford Immunotec
Beckman Coulter
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more